Skip to main content
Publish date:

Osiris Has Positive Data

Shares are up 11% on the news.

Osiris Therapeutics

(OSIR) - Get Osiris Therapeutics, Inc. Report

shares jumped Friday after the company announced positive clinical trial data of its experimental Crohn's disease treatment Prochymal.

The company's shares rose 11.8% to $16.79.

In midstage trials of the drug, treatment with two of the stem cell-based infusions led to a statistically significant decrease in disease activity according to a measure of patient symptoms. With relatively low doses and a short treatment course, all patients evaluated in the trial saw a reduction in the severity of the disease within 28 days, the company says.

TheStreet Recommends

The trial involved patients with moderate to severe Crohn's disease where standard treatments like steroids and

Johnson & Johnson's

(JNJ) - Get Johnson & Johnson Report

Remicade failed.

Earlier this month Osiris received regulatory approval in Canada to conduct trials on the treatment for a life-threatening immune system reaction called graft-vs.-host disease, which occurs in patients who receive transplants or donated bone marrow.